UNSPSC 51332861: Pecazine hydrochloride

This classification denotes a dopamine antagonist C19H22N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TIW15Q5R21, chemically known as mepazine hydrochloride, (+/-)-, but more generally known as pecazine hydrochloride, which bears US NIH Compound Identifier 102907. Most nations, for tariff and trade purposes, schedule pecazine hydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, PECAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCCC(C1)CN2C3CCCCC3SC4C2CCCC4.CL.

UNSPSC 51332861 Pecazine hydrochloride is a Commodity code nominally designating a specific pharmaceutical compound, but state and local governments show minimal recent procurement activity directly matching this narrow product specification. The three most recent opportunities tagged to this code involve broader pharmaceutical and drug-management categories — naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals — rather than pecazine hydrochloride specifically. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP), indicating that pharmaceutical procurement flows through health departments, state agencies, and regional purchasing cooperatives rather than through a single concentrated buyer type. The actual work solicited ranges from emergency-response medications (naloxone and drug deactivation systems) to supply-chain restructuring initiatives for prescription fulfillment and broad-spectrum generic pharmaceutical contracting across participating jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota based on recent postings, with the MMCAP cooperative extending reach to additional states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multi-vendor contracts for generic pharmaceuticals and OTC products through authorized wholesalers. The code shows limited direct demand for pecazine hydrochloride as a standalone product line; business development focus would benefit from tracking health department and state agency procurement activity under broader pharmaceutical family codes rather than pursuing this narrow commodity specification.